Marketing leadership built for the realities of biotech, pharma, genomics, diagnostics, and life sciences — where scientific credibility, regulatory constraints, and long buyer cycles demand a different kind of commercial expertise.
Life sciences companies face commercial challenges that require sector fluency — not just marketing expertise. The buyers are scientists, clinicians, procurement officers, and payer decision-makers. The regulatory environment shapes every claim you can make. And the sales cycle can span 12 to 36 months.
Life sciences buyers demand rigor. But a messaging approach that reads like a scientific abstract won't move procurement decisions. The gap between scientific accuracy and commercial clarity is where most life sciences marketing fails.
What you can say — and how you can say it — is shaped by FDA guidance, promotional compliance requirements, and legal review. A fractional CMO who doesn't understand these constraints creates exposure. One who does builds messaging that's compelling and defensible.
Life sciences procurement typically involves KOLs, clinical champions, lab directors, supply chain, and finance — each with different criteria and communication preferences. Marketing must support all of them simultaneously.
Biotech and diagnostics companies often have 18 to 36 month sales cycles — but investor runway that demands pipeline momentum now. Marketing needs to generate qualified pipeline fast while respecting the reality of how enterprise life sciences deals close.
Many life sciences companies reach commercialization having invested deeply in R&D and regulatory — and minimally in marketing and sales infrastructure. Building that from scratch requires someone who's done it before.
Life sciences marketing has historically lived at conferences and in peer-reviewed literature. Digital demand generation and SEO/AEO strategies are increasingly important — but most life sciences marketers lack the digital fluency to execute them.
BentonNewell provides the senior commercial marketing leadership that life sciences companies need to move from scientific proof to market traction — and from early customers to scalable pipeline.
Dana Newell has built go-to-market strategy for life sciences companies from scratch, including market entry strategy, commercial messaging, and pipeline infrastructure. This is not a generalist applying B2B templates to your sector — it's someone who understands the gap between scientific language and commercial language, and knows how to bridge it without sacrificing either.
Start the ConversationBentonNewell works best with life sciences companies that have a validated product or platform and are ready to build a repeatable commercial motion — whether that's a first commercial launch or a market expansion.
Genomic testing, cell & gene therapy, precision medicine, molecular diagnostics
Clinical diagnostics, companion diagnostics, point-of-care testing, laboratory services
Contract research organizations, lab services, regulatory consulting, and clinical services companies
Specialty pharmaceutical companies with B2B commercial needs — payer strategy, formulary access, and HCP engagement
Dana Newell has built life sciences go-to-market strategy from scratch — not adapted general B2B frameworks to fit. The commercial launch playbooks, messaging architectures, and pipeline infrastructure she develops are built for the specific realities of regulated-industry B2B selling: long cycles, multi-stakeholder buying committees, and buyers who expect scientific rigor from their vendors.
BentonNewell also brings operational depth — P&L accountability across portfolios reaching $200M in annual revenue — which means the growth strategy we develop is grounded in what your organization can actually execute at your current stage and resource level.
A fractional CMO for a life sciences company leads commercial launch strategy, translates scientific and clinical evidence into messaging that moves procurement decisions, builds KOL and conference engagement programs, and develops the digital demand generation infrastructure that most life sciences organizations lack.
By developing a messaging architecture with distinct layers: technically precise language for scientific and clinical audiences, and clear economic and workflow language for procurement, lab directors, and finance. The claim substance stays constant; the framing changes by audience. All commercial claims should be reviewed through your existing regulatory and legal process.
No. BentonNewell provides commercial marketing and operations leadership, not regulatory affairs or legal services. We build messaging designed to be defensible and work within your constraints, but promotional review and regulatory sign-off remain with your regulatory, medical, and legal teams.
Most engagements start with a 30-minute discovery call. No pitch — just a direct conversation about where you are and where you need to go.
Schedule a Discovery Call